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Abstract
Basic phospholipase A2 was identified from the venom of the eastern diamondback rattlesnake. The Crotalus adamanteus
toxin-II (CaTx-II) induced bactericidal effects (7.8 mg/ml) on Staphylococcus aureus, while on Burkholderia pseudomallei
(KHW), and Enterobacter aerogenes were killed at 15.6 mg/ml. CaTx-II caused pore formation and membrane damaging
effects on the bacterial cell wall. CaTx-II was not cytotoxic on lung (MRC-5), skin fibroblast (HEPK) cells and in mice. CaTx-II-
treated mice showed significant wound closure and complete healing by 16 days as compared to untreated controls
(**P,0.01). Histological examination revealed enhanced collagen synthesis and neovascularization after treatment with
CaTx-II versus 2% Fusidic Acid ointment (FAO) treated controls. Measurement of tissue cytokines revealed that interleukin-1
beta (IL-1b) expression in CaTx-II treated mice was significantly suppressed versus untreated controls. In contrast, cytokines
involved in wound healing and cell migration i.e., monocyte chemotactic protein-1 (MCP-1), fibroblast growth factor-basic
(FGF-b), chemokine (KC), granulocyte-macrophage colony-stimulating factor (GM-CSF) were significantly enhanced in CaTx-
II treated mice, but not in the controls. CaTx-II also modulated nuclear factor-kappa B (NF-kB) activation during skin wound
healing. The CaTx-II protein highlights distinct snake proteins as a potential source of novel antimicrobial agents with
significant therapeutic application for bacterial skin infections.
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Introduction
Antimicrobial proteins and peptides play a major role in innate
immunity by interacting directly with bacteria and killing them
[1]. These multifunctional proteins have wound healing activity
and receptor-mediated effects on eukaryotic cells [2]. Previously
reported mammalian proteins and peptides such as defensins [3],
cathelicidins [4], and peptide LL-37 [5] can cause hemolysis of
human erythrocytes and are cytotoxic at higher doses that might
adversely affect wound healing [6], [7]. In addition, emergences of
multi-drug resistant (MDR) bacteria generated by specific
mutations on antibiotic targets, and acquired by transposon genes
[8], are one of the important healthcare concerns for long-term
management. Antibiotics used for treatment of Staphylococcus aureus
infected surgical wounds and other skin related infections include
methicillin [9], vancomycin [10], glycopeptides [11], and beta-
lactams [12]. Following S. aureus infection, wound healing after
treatment with some of these antibiotics has been reported to be
only moderately successful in many cases [13].
However, the prevalence of bacterial resistance to conventional
antibiotics has prompted an intensive search for new therapeutic
agents including various antimicrobial peptides of animal origin
[14]. Proteins/peptides with potent antimicrobial activity have
been found in a wide variety of organisms, including snakes. Their
venom, particularly crotalidae venoms [15], is a rich natural
source for discovery and development of novel antimicrobial
agents. Crotapotin, a secretory phospholipase A2 isolated from the
venom of Crotalus durissus terrificus, shows antibacterial activity [16]
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as well as antiviral activity against the human immunodeficiency
virus [17], [18]. Crotamine is a small basic myotoxin from South
American rattlesnake (Crotalus durissus terrificus) killed via membrane
permeabilization of Escherichia coli with the MICs ranging from 25–
100 mg/ml at 1–2 h and fail to show any hemolytic activity to
erythrocytes. Crotamine antimicrobial peptides (AMP) structure
similar to that many class of beta-defensin [19]. Acidic PLA2 [20],
both Asp49 and Lys49 PLA2 homologues [21], have previously
been shown to possess bactericidal activity [22]. A cationic protein
isolated from venom of the inland taipan (Oxyuranus microlepidotus)
selectively and dose-dependently kills Gram-positive bacteria
through membrane disruption [23]. These molecules are very
attractive because of their biochemical diversity, broad spectrum
of activity against enveloped viruses, bacteria, fungi, protozoa,
parasites, and promotion of wound healing [25], [26]. The eastern
diamondback rattlesnake (Crotalus adamanteus) belongs to the family
Viperidae (subfamily Crotalinae) and is widely distributed in the
United States [27]. Many venom enzymes from various species,
including PLA2, hyaluronidase, L-amino acid oxidase, metallopro-
teinases, as well as myoprotein-CAM-protein and hemorrhagic
protein possess potent pharmacological effects such as myotoxic,
neurotoxic and edematogenic activities [26]. However, relatively
very little is known regarding the antimicrobial activity of C.
adamanteus venom [15] or its components. The aim of the present
finding was to evaluate the antimicrobial and wound healing
activity of a C. adamanteus venom protein (CaTx-II) in a mouse
model for S. aureus wounds.
Materials and Methods
Venom
Required quantities (10 g) of the crude venom of Crotalus
adamanteus (Viperidae: subfamily Crotalinae) were purchased from
Venom Supplies Pte Ltd, Tanuda, Southern Australia, and stored
desiccated at 4uC in individual containers at the Department of
Anatomy, NUS, Singapore.
Purification of Protein (CaTx-II)
Crotalus adamanteus venom (1 g) was dissolved completely in
10 ml of 1 M Tris-HCl (pH 7.4), and after centrifugation at
18006g for 15 min, the clear yellowish solution was sterilized by
filtration through a 0.22 mm membrane filter (Nalge Nunc
International, Rochester, New York, USA). Venom samples
(1 ml) diluted in 9 ml of Tris-HCl was then injected into a
Superdex G-75 column attached to a high performance liquid
chromatography system (HPLC, AKTA GE Healthcare, Den-
mark). Eluents (1 ml fractions) were monitored at 280 nm and
collected in 1.5 ml eppendorf tubes. All the fractions were tested
for enzymatic and antibacterial effects, and the fraction that
showed the highest enzymatic and antibacterial effects were then
subjected to reverse-phased liquid chromatography (RP-HPLC)
via a C18 column (4.66150 mm, Phenomenex, Upsala, Sweden),
using a linear gradient of aqueous acetonitrile (80%) in 0.1%
trifluoroacetic acid (Sigma Aldrich Co, St Louis, Missouri, USA) at
a flow rate of 1.0 ml per min. Subsequent purification of active
fractions were derived by using a C8 RP-HPLC column (100 A˚,
4.66250 mm) [1].
Sodium Dodecyl Sulphate Polyacrylamide Gel
Electrophoresis (SDS-PAGE)
C. adamantetus RP-HPLC fractions, and the final purified
fraction of protein (CaTx-II), were analyzed by SDS-PAGE
according to Laemmli [28]. The molecular weights of protein
bands were determined using standard markers (Bio-Rad,
California, USA). Protein concentrations were determined by
Lowry’s method [29].
Phospholipase A2 (PLA2) Activity
The PLA2 activity of Crotalus adamanteus venom, fractions, and
purified proteins were determined as described [1], with slight
modifications. Each of the above sample solutions (containing
20 mg protein concentration) of 180 ml was added to the substrate
solution containing 5 mM Triton X 100, 5 mM phosphatidyl-
choline (Sigma Co, St. Louis, Missouri, USA), 2 mM HEPES,
10 mM calcium chloride (Merck & Co., Inc, New Jersey, USA)
plus 0.124% bromothymol blue dye (wt/vol) in water (pH 7.5).
After incubating for 10 min at 37uC, absorbance was determined
at 590 nm in a microtiter spectrophotometer (Research Instru-
ment, Virginia, USA). Results were expressed in nmoles of acid
per minute per mg of venom protein.
Mass Spectrometry, Amino Acid Composition, and
Sequencing Analyses
The molecular mass of CaTx-II was analyzed using matrix-
assisted laser desorption time of flight mass spectrometry (MALDI-
TOF/MS) in positive ionization mode. Alpha-cyano-4-hydroxy-
cinnamic acid used to perform with a Voyager-DE STR (Applied
biosystems, Farmingham, Massachusetts, USA). Amino acid
composition and sequencing analyses were performed as described
previously [1]. The terminal sequence of CaTx-II samples were
performed at the Protein and Proteomic Center, Department of
Biological Science, NUS, Singapore using a fully automated ABI
Procise 494 protein sequencer (Applied Biosystem,) system that
employs Edman’s degradation reaction for sequential separation of
N-terminal amino acids.
In vitro Antimicrobial Assays
Bacterial cultures of Burkholderia pseudomallei (TES), Burk-
holderia pseudomallei (KHW), Escherichia coli, Enterobacter
aerogenes, Klebsiella pneumoniae, Streptococcus pneumoniae,
Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, and
Staphylococcus aureus were obtained from the Department of
Microbiology, NUS, Singapore. Venom fractions and purified
CaTx-II were tested for antimicrobial activity. Bacteria were
grown in Mueller Hinton (MH) and Tryptic Soya (TS) broth
(Oxoid Limited, Basingstoke, Hampshire, UK) to exponential
phase (0.5–1.56106 colony forming units (CFU per ml)) with an
A600 of 0.8, representing 12,000 cfu/ml. 20 ml of MH or TS agar
medium was poured into each petri dish (140 mm620 mm)
obtained from Sterilin Limited, UK. After solidification, bacteria
were swabbed uniformly onto the agar surface by a sterile cotton
swab. 20 ml of each test sample (250 mg/ml) was applied to a sterile
blank disc (6 millimeter in diameter, BD Bioscience, New Jersey,
USA) placed on the surface of the MH and TS agar medium, and
incubated at 37uC for 24 h. The blank disc containing sterile
water (20 ml) served as a negative control, while the commercially
available antibiotic discs of chloramphenicol (30 mg/disc) and
streptomycin (30 mg/disc) served as positive controls. Three
replications were used for each assay and effects were recorded
as a clear zone of inhibition, measured diameter in mm, after
incubation [1], [30].
In vitro Bactericidal Activities of CaTx-II
Minimum Inhibitory Concentrations (MICs) of CaTx-II against
different bacteria were determined by the MH and TS broth
dilution method [31]. A single bacterial colony was used to
inoculate each MH and TS broth (5 ml/tube) subsequently
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incubated at 37uC for 6–8 h (exponential-phase cells) before
adjusting with sterile medium to a 0.5 McFarland turbidity
standard. The adjusted bacterial cultures were diluted to
approximately 105–106 CFU/ml before using in the MIC assays.
Bacteria (50 ml) were introduced into each well (containing 100 ml
of medium) of a sterile 96-well plate, followed by addition of
another 50 ml of serially diluted CaTx-II (250, 125, 62.5, 31.25,
15.6, 7.8 and 3.9 mg/ml). 100 ml of medium containing bacteria
served as a control, and 100 ml of medium alone served as a blank.
Plates were incubated for 24 h at 37uC, and inhibition of bacterial
growth was determined by measuring turbidity at 560 nm. Each
MIC was determined from three independent experiments. The
lowest concentrations required for inhibiting the bacterial growth
(MICs) were calculated by statistical analysis [32]. Minimum
bactericidal concentrations (MBCs) were determined as described
by Perumal Samy et al, [1]. Briefly, log-phase bacteria were
obtained from MH and TS broth cultures, and their concentration
adjusted to 105–106 CFU/ml. Bacterial suspensions (50 ml) were
incubated at 37uC for 24 h with 50 ml of CaTx-II (250–3.9 mg/ml)
and 100 ml of MH and TS broth in a 96-well plate. To assess
bacterial viability, these broth cultures were plated on MH and TS
agar and counted following 24 h of growth at 37uC. The
percentage of bactericidal effects was calculated versus bacterial
control.
Scanning Electron Microscope (SEM)
Bacterial cells were grown in MH and TS broth (5 ml per tube)
to an exponential phase. Approximately 26106 CFU/ml were
then centrifuged at 12,0006g for 10 min at 4uC, washed twice
with 2 ml of 10 mM sodium phosphate buffer, and resuspended in
2 ml of the same buffer. The bacteria were incubated for 30 min
with different concentrations of CaTx-II, depending on their pre-
determined MIC values for each strain (i.e., 7.8 mg/ml for S. aureus
and B. pseudomallei (KHW), 15.6 mg/ml for B. pseudomallei (TES)
and 31.25 mg/ml for E. aerogenes, P. vulgaris, and 62.5 mg/ml for P.
mirabilis. After incubation, each sample was spread onto a poly L-
lysine (Sigma Aldrich, St Louis, Missouri, USA) coated glass slide
to immobilize bacteria at 37uC for 24 h. The bacteria were fixed
with 2.5% glutaraldehyde in 0.1 M sodium phosphate buffer,
extensively washed with the same buffer, and dehydrated with an
ethanol gradient (50–100%). After critical-point drying and gold
coating, the samples were observed with a Philips XL 30
microscope [1].
Cell Culture
Human lung (MRC-5) and skin fibroblast (HEPK) cells were
purchased from the American Type Culture Collection (Virginia,
USA), and the cell proliferation Kit II was from Roche Applied
Sciences, Indianapolis, Indiana, USA. Sterile Roswell Park
Memorial Institute (RPMI) medium, fetal bovine serum (FBS),
10 mM phosphate buffered saline (PBS, pH 7.4), and 10 mM
HEPES were purchased from the National University Medical
Institute (NUMI), Singapore. All chemicals were of analytical and
cell culture grade.
In vitro Cytotoxicity
The MRC-5 and HEPK cells were cultured in 72 cm2 flasks to a
density of 106 cells per flask in RPMI as well as Dulbecco’s
Modified Eagle Medium (DMEM) culture medium, supplemented
with 10% FBS and 1 ml of HEPES. Cell viability was measured
using tetrazolium salts (XTT) as described previously [33]. Briefly,
the cells were allowed to adhere to the flask bottom overnight at
37uC in a humidified atmosphere of 5% CO2 and 95% air. Cells
were split and reseeded into new flasks, etc. To analyze the
cytotoxic effects, CaTx-II was applied to cultured fibroblasts tested
at different concentrations (15.6–2000 mg/ml) in a 96 well plate.
The assay plates were incubated at 24 and 48 h time intervals. Cell
proliferation was spectrometrically quantified using an ELISA
plate reader at 490 nm (Bio-Rad, Hercules, California, USA). All
assays were performed in triplicate (n = 3).
Cytolysis Determination by Lactate Dehydrogenase
(LDH) Release
The cytotoxicity of CaTx-II upon human cells (lung and skin
fibroblasts) was evaluated by measuring LDH release using a
cytotoxicity detection kit (Roche Mannheim, Germany). Cells
(106) were cultured in 96-well micro titer plates with RPMI and
DMEM medium (NUMI, Singapore) supplemented with 10%
(vol/vol) FBS and 1 ml of penicillin/streptomycin (1 x). CaTx-II
was added into three wells per dose (15.6–2000 mg/ml), while cells
without any treatment served as a control. The cells were further
incubated at 37uC in the presence of 5% CO2 for 24 and 48 h.
After incubation, the LDH released into the culture medium from
each well was collected following centrifugation at 10,0006g, 4uC
for 5 min. A 200 ml aliquot was used for the quantification of cell
death and lysis, based on LDH released from the cytosol of
damaged cells into the supernatant. The assay was performed in
triplicate [34].
Mice
Pathogen free, 8–12 weeks old male Swiss Albino mice (body
weight 25–30 gm) were obtained from the Animal Breeding
Center, Sembawang, Singapore. The animals were maintained for
12 h under light/dark conditions, and were given appropriate diet
plus water ad libitum. All experimental animals were approved by
the ethics committee, NUS, Singapore (Approval number 055/
2007).
In vivo Toxicity (Mice)
The toxic effect of purified CaTx-II was studied using a
modified method previously reported [1]. The toxic effect of
rattlesnake venom and CaTx-II was assessed in Swiss Albino male
and female mice (1–14 mg/kg, body weight) by intraperitoneal
(i.p.) injection in 200 ml of PBS. Six animals per dose were used,
and the mortality recorded.
Antibodies
Monoclonal or polyclonal antibodies (anti-mouse type I collagen
and anti-rat CD68, Santa Cruz, California, USA) and secondary
antibodies labeled with FITC (Sigma Co., St. Louis, Missouri,
USA) or Cy3 (Santa Cruz, California, USA), and DAPI stain
(Daiko, Japan). All other reagents were of analytical grade (Roche,
Germany).
Skin Wound Preparation and Macroscopic Observation
Mice (n= 6 per group) were anesthetized with meditorin and
ketamin injections (i.p., 20 and 100 mg/kg body weight,
respectively), and their skin hair from the back shaved with a
sterile razor blade. After wiping the shaved area with 70% ethyl
alcohol, an incision 2 cm (full thickness of the wound
4 mm65 mm in length and width) was made. Fifty microliters
of S. aureus (106 cfu/ml) suspended in growth medium in sterile
PBS were applied onto the wound region. Mice were separated
into individual cages and kept for 2 days prior to topical
application of CaTx-II (10 mg/kg, body weight), antibiotic (2%
FAO) and untreated wound control (WCtrl). Wound healing of the
animals was monitored daily by measuring the area of wound
Wound Healing Action of Venom Protein
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closure with a tracing paper at 0–16 days. The wound healing was
then analyzed and the percent reduction of original wound area
calculated. Animals were killed after 16 days by excess CO2
inhalation, and the skin biopsy samples collected from the bisected
center from the skin wound for biochemical studies [35]. For
analysis of collagen and pro-inflammatory cytokines, wound tissues
were frozen immediately in liquid nitrogen and stored at 280uC
until assay time.
Immunohistochemistry
For H & E staining, sections of skin were fixed in 4%
paraformaldehyde in PBS for 16 h before embedding into
paraffin. Thin sections (7 mm ) were cut and processed in an
alcohol series (50–100%) for 5 min, stained with H & E for 3 min,
and then rinsed in tap water for 3 min, before mounting on glass
slides with an embedding media of Histo-Clear (Merck & Co, New
Jersey, USA). The sections were examined under the microscope
(Carl Zeiss Inc., Microimaging, LLC, Thornwood, New York,
USA). Masson’s Trichrome staining was performed for identifica-
tion of collagen [36]. For immunohistochemical staining, excess
tissues were trimmed down and 7 mm thick paraffin sections were
used to detect different antigens. Type I collagen deposits were
immunodetected according to the described protocol. Tissue
sections were incubated overnight with the primary antibodies
(1:50 or 1:100 dilutions for collagen, and 1:200 for CD-68) at 4uC,
washed three times in PBS, and then incubated with peroxidase-
conjugated secondary antibodies (1:1000 in blocking solution) for
5 min. Sections were counterstained with 4, 6-diamidino-2-
phenylindole (DAPI) (Invitrogen, Carlsbad, California, USA) and
stored at 4uC. The sections were examined by a Laser Confocal
microscope (Olympus Imaging America Inc., Center Valley,
Pennsylvania, USA) connected to software (Flow view, FV10.AS),
version (2.0 viewer).
Measurement of Collagen in Wound Tissues
Collagen content of skin wounds were determined by an ELISA
using an assay kit for mouse type I collagen (Chondrex, Inc.,
Redmond, Washington, USA) according to the manufacturer’s
instructions. Briefly, the microtiter plate was washed 3 times and
blocked with 100 ml of blocking buffer solution A for 1 h at room
temperature. Skin tissues (100 mg) were cut into small pieces by
sterile razor blade, each skin sample was homogenized in 0.5 ml of
SDS-buffer, (pH 7.6) by a variable speed tissue homogenizer
(Model 7000, Eberbach Corporation, Michigan, USA). Homog-
enate was centrifuged (10,0006g, at 4uC for 5 min) to remove the
supernatant containing the soluble protein and diluted in
1:1000 mg/ml of solution B. Sample, standard, or blank solution
B (100 ml) was added to the wells in triplicate and incubated over
night at 4uC. After 24 h, the plates were washed 3 times with
16wash buffer, and the secondary antibody (100 ml) introduced
into each well. Following incubation at room temperature for 2 h,
the plates were washed 3 times with wash buffer, incubated with
OPD solution (100 ml/well) for 30 min at room temperature, and
50 ml of sulfuric acid (50 mM) added to stop the reaction before
reading the OD at 490 nm.
Extraction of Wound Samples
Skin wound tissues were excised by using a sterile razor blade to
include the surrounding wound tissues (100 mg weight of tissue
taken per animal) 16 days after treatment. The samples were
frozen in liquid nitrogen and stored at 280uC until analysis. The
tissue samples were homogenized in tissue protein extraction
reagent (T-PER containing 25 mM bicine and 150 mM sodium
chloride, pH 7.6, including protease inhibitor cocktail purchased
from Thermo Fisher Scientific (Rockford, Illinois, USA) and
stored at 280uC prior to analysis. After dilution of the
homogenates with MH and TS broth, 20 ml of each sample was
swabbed on the MH and TS agar plates and incubated at 37uC for
24 h. Bacterial colonies were counted and CFU/ml calculated for
the different treatment groups.
Analysis of Proinflammatory Cytokines
Skin wound tissues were collected and extracted by standard
protocols. Total protein of the skin homogenates were determined
by using a Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, California, USA). The concentrations of proinflamma-
tory cytokines interleukin-1 beta (IL-1b), IL-6, IL-10, chemokine
(KC), tumor necrosis factor-alpha (TNF-alpha), fibroblast growth
factor-basic (FGF-b), granulocyte-macrophage colony-stimulating
factor (GM-CSF), monocyte chemotactic protein-1 (MCP-1) and
macrophage inflammatory protein-1 beta (MIP-1b) levels were
measured by using a commercially available multiplex cytokine kit
(Mouse Inflammation Kits, BD Pharmingen, San Diego, Califor-
nia, USA) according to the manufacturer’s instructions.
Western Blot Analysis
Vascular endothelial growth factor (VEGF) antibody was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Phospho-specific anti-p65 (Ser 536) was purchased from
Cell Signaling (Beverly, MA, USA). b-actin antibody were
obtained from Sigma Chemicals Co (St. Louis, MO, USA). To
determine the levels of various proteins, skin wound tissue extracts
were prepared and fractionated by SDS-polyacrylamide gel
electrophoresis (PAGE) as described previously [37]. After
electrophoresis, the proteins were electro-transferred to a nitro-
cellulose membrane, blocked with 5% nonfat milk to minimize
non-specific binding, and probed with various antibodies (1:1000)
overnight at 4uC. The blot was washed, exposed to HRP-
conjugated secondary antibodies for 2 h, and the expression of
various proteins was detected by chemiluminescence emission
(ECL; GE Healthcare, Little Chalfont, Buckinghamshire, UK).
Statistical Analysis
Each experimental group, six animals were used for the wound
healing study (n= 6). All assays were performed in triplicate. Data
are presented as mean 6 SD (standard deviation). Statistical
analysis was carried out by ANOVA for comparison of multiple
groups, or by Student’s t-test for two-group comparisons. Levels of
significance are indicated as *p,0.01, **p,0.05.
Results
Purification and Identification of Protein (CaTx- II)
Molecules
Purification of C. adamanteus venom by Superdex G-75 gel-
filtration chromatography provided four (CA1–CA4) fractions
(Fig.1 A). Upon fractionation of the enzymatically and antimicro-
bially most active fraction (CA2) by C18 RP-HPLC chromatog-
raphy (Fig. 1B), it was further resolved into four fractions (CA-F1
to CA-F4). The antimicrobially-active fraction CA-F1 was further
fractionated through a C8 column to obtain a purified protein
identified as CaTx-II. Each fraction was purified in subsequent
steps to homogeneity (Fig. 1 C–D). Preliminary mass analysis
(MALDI-TOF/MS) revealed a 13675.34 kDa protein (Fig.1 E).
SDS-PAGE (Fig.1 F) shows a single band with a molecular mass of
15 kDa. Elucidating PLA2 activity of column fractions showed
variable levels of PLA2 activity, with the fraction containing CaTx-
II displaying higher levels of PLA2 activity than that of other
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fractions or crude venom (Fig. S1 A–D). In addition, CaTx-II
possessed the highest activity of any PLA2 purified from C.
adamanteus venom.
Amino Acid Analysis
The N-terminal amino acid sequence of CaTx-II is shown in
table S1. When aligned and compared with the N-terminal
sequences of other snake venom PLA2s, the sequence of CaTx-II is
quite homologous with basic PLA2s isolated from other crotalidae
venoms, with a sequence similarity of 70–80% found with the Lys-
49 PLA2 sequence of crotapotin from C. adamanteus venom.
Antimicrobial Activity of CaTx-II
When screened against a wide range of Gram-negative and
Gram-positive bacteria using a disc-diffusion assay, CaTx-II
showed very strong antimicrobial effect against S. aureus, B.
pseudomallei (TES & KHW), E. aerogenes, P. vulgaris and P.
mirabilis. (Fig. S2 A). It exerted maximum inhibition zones against
S. aureus and B. pseudomalleii (KHW) compared to those of
chloramphenicol or streptomycin (30 mg/disc). The most sensitive
bacterium to CaTx-II was S. aureus, whereas against Gram-
negative B. pseudomallii (strain KHW), CaTx-II was more active
even at a lower dose of 20 mmole range than the antibiotics
(30 mg). Similar effects were also observed with the less purified
fraction (CA-F1) (Fig. S2 B). At higher concentrations, the crude
venom showed more potent antimicrobial activity against the
multi-drug resistant B. pseudomallei (KHW) than P. aeruginosa
(Fig. S2 C). The CA-CV crude venom, CA-F1 isolated fractions,
and the purified CaTx-II protein exhibited only moderate activity
against E. coli, P. aeruginosa, K. pneumoniae and S. pneumoniae at the
tested concentration. However, the growth inhibition curves
clearly illustrated that CaTx-II was the most active antimicrobial
agent against S. aureus than other tested fractions or control
antibiotics (Fig. S2 D–E).
Bacteriostatic (MIC) and Bactericidal (MBC) Assays
MICs indicated that CaTx-II had an interesting inhibitory
(bacteriostatic) effect even at the lowest dilutions against S. aureus
(MIC value of 7.8 mg/ml), B. pseudomallei strain KHW and B.
pseudomallei strain TES (MIC value of 15.6 mg/ml). A higher MIC
value (62.5 and 125 mg/ml) was recorded against P. mirabilis, K.
pneumoniae, and P. aerugionsa versus P. vulgaris (31.25 mg/ml) in Fig.
S3. Whereas, bactericidal effects of CaTx-II against S. aureus, and
B. pseudomallei (MBC values of 7.8–15.6 mg/ml) were very powerful
and much more potent on a mole basis versus standard antibiotics
(Fig. S4).
Membrane Damaging Effects of CaTx-II
Further studies were done with CaTx-II to determine what, if
any, overt effects might be seen on bacteria via SEM analysis. As
observed on B. pseudomallii KHW (Fig. 2A–B), B. pseudomallii TES
(Fig. 2C–D), E. aerogenes (Fig. 2E–H), P. vulgaris (Fig. 2I–L), S. aureus
(Fig. 2M–N), and P. mirabils (Fig. 2O–P), the effects of this protein
appeared quite rapidly (24 h) at the tested concentrations (3.9–
250 mg/ml). CaTx-II was potent, even at the low concentrations,
in killing the bacteria very efficiently through damaging the
membrane. Pore formation and membrane-damaging effects of
CaTx-II varied depending upon the bacterium. Although its main
effect is on bacterial cell membranes as the primary target, it is
unclear whether CaTx-II may also act on other intracellular
targets.
Cell Viability & Cytotoxicity
Cytotoxic effects of CaTx-II were examined on human lung and
skin fibroblast cells. Cell viability was not affected even at higher
concentrations of 500 mg/ml (Fig. 3A–D). There were no
morphological changes, indicating that the cells remain intact
with no swelling or death evidenced at higher (up to 500 mg/ml)
concentrations of CaTx-II in a time-dependent manner on skin
(Fig. 3E–F) and lung (Fig. 3K–L).
Release of LDH from Cells
LDH results revealed that exposure of the lung and skin
fibroblast cells to CaTx-II (up to 500 mg/ml) were not cytotoxic up
to 48 h (Fig. 3G–J). However, a higher dose (500 mg/ml) of CaTx-
II did not cause LDH release and induced cell death or lysis.
However, the growth of fibroblast cells was not affected, especially
at the treatment dose up to 500 mg/ml.
Toxicity Study in Mice
The CaTx-II did not show toxic effects or kill mice up to
14 mg/kg, b.w for 2 weeks, and in fact they behaved like controls
given saline only.
Wound Healing
CaTx-II treated mice showed strong wound healing activity
following S. aureus infection with a significant reduction in the
wound area (60%) after 8 days, compared to that of wound control
mice (P,0.01). In contrast, the antibiotic fusidic acid ointment
(FAO) treated mice showed only 40% reduction of wound size
after 8 days. The CaTx-II treated wounds contracted faster and
were completely healed by 16 days as compared with that of the
FAO-treated mice. We provide definitive evidence that CaTx-II
influences crucial roles in the wound-healing process by regulating
leukocyte infiltration, angiogenesis, neovascularization and colla-
gen deposition (Fig. 4 A).
Collagen Content in Wound Site
The collagen content in wound sites was measured by ELISA.
The CaTx-II treated animals showed significantly increased levels
of collagen content (p,0.05) as compared with the wound control
(WCtrl) animals. CaTx-II treated mice showed a 50% increase in
collagen levels after 8 days versus wound control or FAO treated
mice. At 16 days post-treatment, the collagen content was
increased to 80% in the CaTx-II treated group (Fig. 4 B–C),
and 70% in FAO treated group as compared to that of wound
control mice.
Histological Re-epithelialization
Histopathological examinations were carried out on the wounds
of treated and untreated mice after 16 days. When compared to
the CaTx-II treated wound, the untreated wound epidermis was
thin and disorganized; indicating delayed healing and its non-
Figure 1. Purification of Crotalus adamanteus toxin-II (CaTx-II) from Eastern Diamondback Rattlesnake venom. (A) High Performance
Liquid Chromatography (HPLC) profiles of C. adamanteus crude venom from a Superdex G-75 column, (B–D) Reverse-phase (RP)-HPLC
chromatograms from Sepharose C18 and C8 columns, (E) Molecular mass of pure CaTx-II, (F) Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) profile of RP-HPLC fractions, lanes indicate: CA-CV C. adamanteus crude venom (1–2), lane (4) homogeneity of CaTx-II
confirmed by SDS-PAGE as 15 kDa of CA-F1 - reverse-phase fraction and (5) marker, 25 mg of protein loaded per lane, respectively.
doi:10.1371/journal.pone.0080199.g001
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involvement in the regeneration and wound healing process (Fig. 4
D). Also, the significant reduction of infiltrated inflammatory cells,
an increase in the formation of blood vessels, and enhanced
proliferation of cells were observed in CaTx-II treated wounds.
There was thick epidermal regeneration that covered completely
the wound area with well-formed granular layers. In addition,
there was extensive epithelialization, vascularisation, and hair
follicle formation in CaTx-II treated mice. The early dermal and
epidermal regeneration in treated mice also confirmed that CaTx-
II had a positive effect upon cellular proliferation, granular tissue
formation and epithelialization (Fig. 4 E). Masson’s Trichrome
staining of control and CaTx-II treated mice after 16 days also
evidently supported the collagen accumulation and its expression,
which is important for wound healing. CaTx-II treated mice
showed a significant accumulation of collagen on mice skin
16 days after the injury (Fig. 4 F), whereas saline injected mice
showed very little deposition of collagen (Fig. 4 G).
CaTx-II Inhibits NF-kB Activation in Skin Wound Model
As NF-kB activation plays a major role in mediating and
modulating gene responses associated with wound healing [38],
the ability of CaTx-II to modulate NF-kB activation in skin wound
model was also investigated. We found that the treatment with
CaTx-II substantially inhibited constitutive p65 phosphorylation
that was observed in wound control mice (Fig. 4 H). Also, the
levels of NF-kB-regulated protein, VEGF, an endothelial cell
Figure 2. CaTx-II damages the bacterial surface as determined by SEM. (NC) Bacteria treated with PBS as a normal control. (A–D) Exposure to
7.8 and 15.6 mg/ml proteins induced mainly membrane-damaging effects upon B. pseudomallei (KHW &TES). (E–H) E. aerogenes, (I–L) P. vulgaris, (M–N)
S. aureus incubated with 7.8 mg/ml of protein show a severely damaged cell membrane (disorganization), formation of membrane blebbing, and
release of cellular content (cytoplasmic eruption). (O–P) P. mirabilis exposed to 62.5 mg/ml of CaTx-II have surface roughening and membrane
damaging effects after 24 h. All samples were processed at 24 h for SEM analysis as described in the experimental procedures.
doi:10.1371/journal.pone.0080199.g002
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specific mitogen that plays an important role in vascular
development and wound healing [54] was also suppressed upon
treatment of mice with CaTx-II (Fig. 4 H).
Bacterial Counting and Positive Cells at Wound Site
Wound tissues of treated and untreated mice were collected for
determining the bacterial load as a percentage of CFU/wound of
Figure 3. In vitro cytotoxicity was evaluated by XTT-assay. (A–D) CaTx-II incubated with human lung (MRC-5) and skin fibroblast (HEPK) cells
using different concentrations (15.6, 31.25, 62.5, 125, 250, and 500 mg/ml) after 24 h and 48 h incubation. The values are expressed as mean 6 SD of
three replicates (n = 3), Control (Ctrl) cells without any treatment served as a control, (E) Light micrograph showing the normal architecture of skin
fibroblasts, (F) cells exposed to CaTx-II at different concentrations 15.6–500 mg/ml. (K) Lung fibroblasts without any treatment, (L) cells treated with
500 mg/ml concentrations of CaTx-II did not cause morphological changes after exposure (Magnification620), (G–J) Quantification of cell death and
lysis was based on lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells into the culture supernatant of the fibroblast cells
(skin and lung) exposed to protein up to 15.6–500 mg/ml concentrations. Cells exposed to CaTx-II at 500 mg/ml showed very low level of cytolysis
after 48 h exposure.
doi:10.1371/journal.pone.0080199.g003
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three observations (Fig. 5 A). Representative data of six mice in
each group were shown. Vascular densities (re-epithelialization)
within the wound bed at 16 days after the injury of CaTx-II or
FAO treated mice and untreated mice with injured skin (control)
were determined using PhotoShop. All the values represent mean
6 SD (n= 6 animals); significance at *P,0.01, **P,0.05
compared with untreated mice wound served as a control.
Immunohistochemical Examination
Significant bacterial reduction (cfu/wound) was found in wound
treated with CaTx-II versus FAO treated and wound control mice
(Fig. 5 A). There was a very high level of positive cells (CD68
marker for keratinocytes) expressed in the protein treated wound
(Fig. 5 B), and accelerated re-epithelializations (Fig. 5 C) compared
with untreated control. Immunostained wound samples of CaTx-
II or FAO treated and wound control mice after 16 days are
shown in Fig. 5 D–F. The sections were stained with collagen
(green), CD-68 antigen (red), or co-localization of collagen plus
CD-68. Wound sections of mouse skin topically applied with
CaTx-II were treated mice skin intensively stained with collagen
(green), CD-68 antigen (red), and a merger of collagen plus CD-
68, indicating an interesting over-expression of collagen as well as
CD-68 antigen maker for keratinocytes as compared to the WCtrl.
The CaTx-II treated wounds expressed or up-regulated more
CD68 positive cells and migration of keratinocytes at the wound
edge than the other groups (Fig. 5 A–C). The FAO treated section
showed less intense staining of collagen and CD-68 antigen than
the treated groups.
Expression of Inflammatory Cytokines
Levels of interleukin 1beta (IL-1b), IL-6, IL-10, TNF-alpha,
macrophage inflammatory protein 1 beta (MIP 1 beta), MCP)-1,
FGF-Basic, KC, and granulocyte colony-stimulating factor (G-
CSF) were measured at 16 days post-treatment in the wound tissue
homogenates. With the exception of IL-10, all cytokines measured
were elevated significantly versus the control group (Fig. 6).
Wounds from both CaTx-II and FAO treated groups contained
significantly low levels of the proinflammatory cytokines TNF-
alpha, IL-1 and IL-6 versus wound controls. The basal layer
keratinocytes at the wound edge showed up-regulated expression
of MIP-1 beta. As a result of this mediator increase, the
inflammatory response to injury might potentially disrupt other
essential phases of wound repair. The reduction in cytokine
content ranged from approximately 75% for TNF-alpha, IL-1, IL-
6 and IL-10, with no differences in the wound content of MCP-1
measured between the groups. MCP-1 was expressed exclusively
around 7 days post-injury, whereas FGF-Basic, KC, and G-CSF
were expressed late (16 days) during the recovery phase. FGF
basic and G-CSF play an important role in wound healing as
components of the cytokine network that regulate co-operation of
development and differentiation of cells during repair.
Discussion
Snake venom phospholipase A2 (svPLA2s) enzymes are classified
into 15 groups and 23 sub-groups. Most of the elapidae and
hydrophidae svPLA2s belong to group I, whereas viperidae
venoms belong to group II. Previously, a number of PLA2s have
been isolated from snake venoms [1], [40]. In this study, we
purified a basic PLA2 (CaTx-II) from the eastern diamondback
rattlesnake (C. adamanteus). Its N-terminal sequence exhibits a high
degree (80%) of homology with crotapotin, the Lys-49 PLA2 from
C. adamanteus venom. PLA2 homologues from Crotalus snake
venoms contain 120–130 amino acids with seven disulfide bridges
[41]. They are calcium-dependent enzymes that hydrolyze fatty
acids at the sn-2 position of phospholipids [42], consisting of
catalytically active and inactive forms [43]. The catalytic activity of
PLA2s depends on the binding of a calcium ion and residue Asp-49
[44]. However, the side-chain atom of lysine residues can play a
similar role to that of calcium, thereby enabling Lys-49 PLA2 to
display interesting catalytic activity [45]. These two types of PLA2s
exert most of their biological properties through relatively large
molecular surfaces encompassing several discrete domains such as
the N-terminal helix and calcium-loop [46].
Antimicrobial Activity
Several antimicrobial proteins and peptides have been identified
from both amphibians [47] and reptiles. These molecules are
attractive in research due to their broad spectrum of activity on
bacteria, viruses and fungi, as well as wound healing effects [1],
[24], [25]. C. adamanteus venoms are broadly active against Gram-
negative and Gram-positive bacteria [48]. The inhibitory and
bactericidal activity of C. adamanteus venom determined against
aerobic and anaerobic microorganisms showed variable activity at
5–20 mg/ml and 480 mg/ml, respectively [49]. This venom was
reported to be equally effective as some conventional antibiotics
like chloramphenicol and ceftazidime [47], and the bactericidal
action might be due mainly to the enzymatic activity of C. adamanteus
venom PLA2. In this study, we report for the first time the broad-
spectrum antimicrobial activity of CaTx-II purified from C.
adamanateuse venom. This PLA2 was most effective against a Gram-
positive (S. aureus) and Gram-negative (B. pseudomallii strain KHW),
with an antimicrobial potency similar to that of antibiotics. CaTx-
II was the most active, showing inhibitory activity even at low
concentrations of CaTx-II (20 mg) as compared with 30 mg for
chloramphenicol and streptomycin.
CaTx-II showed a significant inhibitory effect against S. aureus
and B. pseudomallei strains even at lower concentrations (7.8 and
15.6 mg/ml). These findings are, in contrast with several studies
involving bactericidal activity of snake venom PLA2 enzymes [16],
[17]. Whereas, diverse PLA2 enzyme purified from snake venom
possessed highly potent antimicrobial activity against multi-drug
resistant B. pseudomallei [15]. The reported activity is not only due to a
PLA2, but also the basic Asp-49 PLA2 subunit of C. durissus terrificus
venom and displays bactericidal activity upon E. coli [22]. In this
current study, CaTx-II had minimal effect upon E. coli. In
addition, myotoxic Asp-49 PLA2s and Lys-49 PLA2 homologues
are potent microbicidal components in snake venoms [74].
The ultrastructural assessment of CaTx-II bactericidal effects, as
reported herein, on Gram-positive (S. aureus and E. aerogenes), and
Gram-negative (B. pseudomalleii) bacteria suggest that CaTx-II
ruptures the membrane subsequently and causes cytoplasm loss.
These results clearly provide evidence that CaTx-II acts via its
pore-forming action at 7.8 and 15.6 mg/ml doses. It was previously
reported that the peptide derived from the C-terminus (115–129)
of Lys49 Bothrops asper PLA2 reproduced bactericidal activity
against both Gram-negative (Salmonella typhimurium) and Gram-
positive (S. aureus) bacteria as effectively as its parent molecule [50],
[51]. Besides, the bactericidal effect of Lys49 or Asp49 PLA2 has
been previously reported with the specific membrane-damaging
effects [52], [53]. Most Lys-49 PLA2s contain a high level of basic
and hydrophobic amino acids residues located within the C-
terminal region [54]. PLA2 homologues bind with high affinity to
bacterial lipopolysaccharide (LPS) to block their effects on
macrophage and other targets [51]. An earlier study has shown
that the PLA2-derived peptide interacts with LPS and specifically
the lipid A component from diverse Gram-negative bacteria or
with lipoteichoic acid from S. aureus, and relies on a membrane-
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permeabilizing mechanism to exert its bactericidal effects [51].
LPS is a complex molecule composed of a fatty acid (lipid A), O-
polysaccharide chain and core sugar, inserted into the outer
membrane of Gram-negative bacteria. While Lys interacts with
the anionic phospholipid head groups in the bacterial membrane
surface, the hydrophobic core portion of the peptide can interact
with the lipid bilayer causing membrane disruption [55]. Based on
our previous studies, most snake venom proteins tested for
antibacterial properties induce pore formations (i.e. blebs), likely
resulting in loss of membrane integrity and release of cellular
contents [1], [31].
Several studies reported that the mechanism action of basic
Asp49-PLA2 isolated from Agkistrodon halys venom induced
morphological changes in Gram-negative and positive bacteria
consistent with severe damage that include significant membrane
blebbing and loss of membrane integrity [31]. The damage was
evidenced in E. coli by bothropstoxin-1 (Lys49-PLA2) isolated of B.
jararacussu. Lys49-PLA2s damage artificial membranes by a Ca
2+-
independent mechanism and displayed a potent bactericidal effect
[56]. Bactericidal activity of PLA2 involves both recognition of
anionic sites and the enzymatic degradation of phospholipids in
the membranes of target cells, preferentially of Gram-positive
species [57].
Whereas, acidic PLA2 of Porthidium nasutum caused morpholog-
ical changes consisting of irregular-shaped bacterial cell wall,
cellular debris, and possible leakage due to cell lysis (Vargas et al.,
2012). It well recognized that hydrolysis of the phospholipid
component of the bacterial cell membrane by PLAs is involved in
killing both Gram-positive and Gram-negative bacteria. PLA2 are
able to penetrate the peptidoglycan envelope of Gram-positive
bacteria and gain access to the cell membrane phospholipids.
However, they are capable of hydrolyzing the phospholipids of the
bacterial cell membrane in Gram-negatives only after the
lipopolysaccharide-rich layer is disrupted. Thus the effects on
these bacteria depend on factors that can disrupt the outer
membrane [58].
In vitro/in vivo Toxicity
CaTx-II did affect viability of human lung (MRC-5) and skin
fibroblast (HEPK) cells in a dose- and time-dependent manner. In
vitro assay showed that after 24 and 48 h of treatment, metabolism
was not inhibited at a very high dose of CaTx-II (2000 mg/ml). In
vivo, the CaTx-II (1–14 mg/kg, b.w) did not show toxic effects or
kill mice after 2 weeks, and in fact they behaved like controls. A
previous study showed that the neutral PLA2 from Hemachatus
haemachatus venom is much less toxic in mice than the basic PLA2
from Naja nigricollis venom, with an i.v LD50 of 8.6 and 0.63 mg/
kg, respectively [59]. Similarly the injection of neutral PLA2 into
rats showed convulsant and lethality effects at 7.5 and 15 mg,
respectively. Corresponding values for the basic PLA2 were quite
lower at 0.5 mg per rat. Death appeared due to congestion,
hemorrhage and edema in the lungs. A direct effect on the cardiac
or respiratory system depends upon the route of administration
[54].
Wound Healing
Wound healing is a complex process involving a series of
overlapping, inflammation-based phases [60]. White blood cells
invade the wound region by migrating through the extracellular
matrix (ECM). Fibroblasts subsequently migrate into the injured
site and replace the blood clot with collagen. These latter cells
biochemically alter the ECM by degrading the fibrin and
producing collagen [61]. In mice, when CaTx-II was topically
applied to a wound after S. aureus infection, healing was
significantly accelerated as a result via the contraction of newly
formed connective (granulation) tissue by fibroblasts. Our results
corroborate that recently reporting [61] the formation of
connective tissue by fibroblasts during wound healing. During
the final phase of wound healing (maturation phase), there is
contraction, new tissue formation resulting in a smaller amount of
apparent scar tissue [35]. In addition, protein-based antimicrobials
like CaTx-II can be multifunctional with receptor-mediated effects
on eukaryotic cells that include chemotaxis and wound healing [2],
[3], [62]. Differential expression of antimicrobial proteins/
peptides plays an important role in the susceptibility of patients
with inflammatory skin disorders to infections. In addition, the
neutrophils are abundant in lesions of superficial skin disease
characterized by inflammation and infection with S. aureus [63].
These studies indicate potential roles for antimicrobial peptides in
host immune defense against skin infection.
Interestingly, CaTx-II treatment influences the migration and
proliferation of keratinocytes at the wound edge followed by
proliferation of fibroblasts into the adjacent area. The treated
animals also experienced accelerated neovascularization, granula-
tion tissue formation, and re-epithelialization of the wound as a
result of increased keratinocyte proliferation. Wound healing is
firmly-based upon collagen. Proliferation of fibroblasts and
synthesis of new collagen predominate in the proliferative phase
of the healing process [64]. The quantitative assessment of
collagen deposition rates of both CaTx-II treated and control
groups used for the measurement of wound healing responses after
16 days. CaTx-II treatment leads to better wound healing versus
untreated. Immunohistochemistry studies also indicated that type I
collagen is the most abundant protein component of the
granulation tissue and accumulated more than the surrounding
dermis. Detection of the expression and distribution of CD68 (the
surface marker of macrophages) revealed a more prevalent pattern
in wounds treated with CaTx-II, versus untreated, after 16 days.
Figure 4. Wound healing is accelerated in CaTx-II treated mice than wound control (WCtrl). (A–B) full thickness excision wounds 2 cm
(4 mm65 mm) were created on the dorsal skin of mice after infected with S. aureus (50 ml of 16105 cfu/ml of bacteria). Wounds were treated by
topical application of CaTx-II (10 mg/kg, body weight) or FAO (2%), and wound closure measured and compared with saline-treated control mice
(n = 6, *P,0.05). The protein treatment influenced wound healing after 16 days in mice. Collagen content in wound sites of treated and
control animals were measured by ELISA. (C) There was a significant difference between (CaTx-II) treated animals showing that collagen levels
increased to 50% after 8 days versus controls treated with FAO, (D) the collagen content increased to high levels after 16 days of injury in mice.
Histopathological examination of skin wound samples of control and protein (CaTx-II) treated mice at 16 days after injury. The section stained with H
& E using original magnification (20 x). (E) Wound control mice delayed healing (F) Protein (CaTx-II) treated mice showed significant reduction of
wound area, leukocyte infiltration, re-epithelialization, angiogenesis on 16 days after the injury. Masson’s Trichrome (MT) staining of skin wound
samples of control and protein (CaTx-II) treated mice at 16 days after injury. (G) CaTx-II treated mice showed excellent accumulation of collagen on
mice skin after 16 days post injury, (H) saline received mice showed less stain content of collagen deposition. (I) S. aureus bacteria infected skin
wounds were either untreated or treated with 10 mg/kg, body weight, of CaTx-II for 16 days. CaTx-II inhibits NF-kB activation and the expression of
VEGF in skin wound tissues. Skin wound tissue extracts were prepared and western blot analysis was performed using phospho-specific p65, VEGF
and b-actin antibodies.
doi:10.1371/journal.pone.0080199.g004
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Figure 5. Wound fluid killing assay and determination of positive cells. (A) Wound tissues of treated and untreated mice were collected for
bacterial counting. Values are shown as percentage of CFU/wound of three observations. (B) There was very high level of positive cells (CD68 marker
for keratinocytes) expressed in CaTx-II treated wound. (C) Representative data of six mice in each group were shown, vascular densities within the
wound bed at 8 and 16 days after the injury, with and without treatment, were determined using PhotoShop. All the values represent mean 6 SD.
**P,0.01, *P,0.05 compared with control. Immunohistochemical sections of CaTx-II treated, FAO treated, and untreated skin wound
samples after 16 days injury. (D) The section of CaTx-II treated wound stained with collagen (green), stained with CD-68 antigen, merged or co-
localization of collagen plus CD-68 (original magnification,620). Section of wound control mice skin stained with (E) collagen (green), CD-68 antigen,
merge of collagen plus CD-68. (F) Section of wound FAO treated mice skin stained with collagen (green), CD-68 antigen, and merge of collagen plus
CD-68. (Magnification bars 100 mm).
doi:10.1371/journal.pone.0080199.g005
Wound Healing Action of Venom Protein
PLOS ONE | www.plosone.org 12 February 2014 | Volume 9 | Issue 2 | e80199
Previously, anti-CD68 antibody was used to study the role of
haemoxygenase-1 in wound repair [65].
Inflammatory Cytokines
Inflammatory cells invade the wound tissue within a few hours
after injury [66], and these cells are an important source of
growth factors and cytokines that initiate the proliferative phase
of wound healing. All stages of the wound healing process are
controlled by a wide variety of different growth factors,
chemokines and cytokines [67]. Particularly, the cytokines
influence various processes at the wound site such as stimulation
of keratinocyte, granulation tissue formation [55], fibroblast
proliferation, synthesis of collagen, and breakdown of ECM.
Several cytokines such as IL-1 alpha, IL-1beta, IL-6 and TNF-
alpha play a major role in wound healing. Expression of IL-1
beta, IL-6 and TNF-alpha is strongly up-regulated during the
inflammatory phase of healing [66], [68]. In this study, the
wound control group contained significant elevated levels of all
cytokines with the exception of IL-10 in mice. Wounds treated
with either CaTx-II or FAO showed significantly low levels of
inflammatory cytokines such as TNF-alpha, IL-1 and IL-6
compared with the WCtl. Previously, Mori et al [69] generated
excisional wounds on the back of mice lacking the TNF receptor
p55 and showed more collagen content, angiogenesis and re-
epithelialization. In this current study, the expression of TNF-
alpha was also increased from the early phase of the wound at
4 days. Whereas, the wound control (WCtrl) had up-regulated
expression of MIP-1, and as a result of this mediator there was an
increased inflammatory response to injury that potentially
disrupted other essential phases of wound healing. At the wound
site, CaTx-II enhanced expression of KC, MCP-1, FGF-basic
and G-CSF after 16 days. In addition to leukocyte infiltration,
expression of adhesion molecules and cytokines were reduced
significantly. FGF basic and GM-CSF play important roles in
wound healing as components of the cytokine network that
regulates development and differentiation of cells during wound
healing. Fascinatingly, various growth factors essential for wound
healing, such as TGF-b1, are elevated in the wounds of animals
[70]. Histological data were also supported by increased
expression of TGF-beta 1 at the wound site [64]. However,
studies involving full-thickness excisional wounds generated in
transgenic mice over expressing GM-CSF in the epidermis [70]
Figure 6. Wound cytokine and chemokine levels as determined by an ELISA. Cytokines were quantified from skin wounds treated with
CaTx-II or FAO, compared with untreated wound controls 4–16 days post injury. Cytokine and chemokine levels in skin wound were determined as
described in the experimental procedures. Data are mean6 SD, n = 6 mice per group. Statistical analysis was carried out by ANOVA for comparison of
multiple groups, levels of significance *P,0.01 as compared with the WCtrl group.
doi:10.1371/journal.pone.0080199.g006
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show that GM-CSF stimulates wound healing directly. This
molecule regulates growth/differentiation of various cells that
include keratinocytes and endothelial cells. Keratinocytes actively
control the production of their growth factors in fibroblasts by
release of interleukin-1 (IL-1) alpha and beta, enhancing
expression of growth factors in stromal cells such as keratinocyte
growth factor (KGF) and fibroblast growth factor-7 (FGF-7), and
granulocyte-macrophage colony-stimulating factor (GM-CSF).
These factors strongly stimulate keratinocyte proliferation and
are up-regulated during wound healing [71].
NF-kB is a heterodimeric transcription factor that plays a key
role in inflammatory and immune response [72]. Transcription
of various inflammatory cytokines and CXC chemokines
requires the activation of NF-kB, a major target of IL-1 and
TNF-alpha mediated signal pathway [39]. These cytokines (IL-1
and TNF-alpha) can induce the phosphorylation and subse-
quent degradation of IkB, followed by liberation of NF-kB and
its nuclear translocation. In the nucleus, NF-kB dimers bind to
target DNA elements and activate transcription of immune
and/or inflammatory-associated genes, such as chemokines and
adhesion molecules [73]. Recently, several lines of evidence
indicate that the transcription of VEGF, a potent angiogenic
factor, is also regulated in a TGF-beta/Smads-dependent
manner [74]. TGF-beta 1 is implicated as a key mediator of
collagen synthesis [75]. It activates the kinase activities of its
receptor, which phosphorylated Smad2 and Smad3 associate
with Smad4 and translocate into nucleus, thereby inducing
expression of the target genes. In this study, the ability of CaTx-
II protein to modulate NF-kB activation in a skin wound tissues
was also investigated. We found that the treatment with CaTx-
II substantially inhibited constitutive p65 phosphorylation that
was observed in wound control mice. Also, the levels of a NF-
kB-regulated protein, VEGF [76] were also substantially
suppressed upon treatment of mice with CaTx-II. VEGF
enhances the permeability of local blood vessels [77] and
recently, Peters et al [78] has previously demonstrated substan-
tial expression of VEGF mRNA in proliferating keratinocytes of
the newly formed epithelium during wound healing.
Conclusions
CaTx-II possesses significant sequence similarity with the Lys-
49 PLA2 enzymes. This protein is effective as an antimicrobial
against Gram-positive S. aureus bacteria and Gram-negative B.
pseudomallei and E. aerogenes bacteria versus tested antibiotics. Our
results provide an excitedly new insight upon the antimicrobial
mechanism of a membrane damaging snake venom protein that
includes pore-formation. CaTx-II did not have cytotoxicity on
tested human lung and skin fibroblast cells at high doses. On the
other hand, CaTx-II promotes significantly better wound healing
activity than fusidic acid (FAO) ointment. CaTx-II accelerates
wound healing, faster re-epithelialization, formation of collagen,
as well as enhanced levels of MCP-1, FGF-basic, KC, and G-CSF
after 16 days. Whereas, the wound treated with CaTx-II
significantly inhibited p65 phosphorylation and expression
compared to the wound control. In addition, the levels of NF-
kB-regulated protein, VEGF an endothelial cell specific mitogen
that plays an important role in vascular development and wound
healing in this study. The clinical significance of CaTx-II may be
its utility as a potent wound healing agent for the treatment of
skin wounds. The rapid development of antibiotic resistant
bacteria, with fewer efficacious options available to the physician,
makes it necessary to discover novel antimicrobial agents. Our
findings suggest that snake venoms represent a potentially
widespread source of novel antimicrobial agents that may have
important medical applications in the near, and distant, future.
Supporting Information
Figure S1 Enzyme linked immunoabsorbent assay
(ELISA) based biochemical analysis. (A–B) PLA2 activity
was compared with the C. adamanteus crude venom (CA-CV),
different purified fractions (CA-F1-CA-F4), and CaTx-II. (C–D)
Total protein contents were determination. Values are mean 6
SD of three replicates, the highest PLA2 activity containing
fraction is indicated by asterisks.
(TIF)
Figure S2 In vitro antimicrobial activity of CaTx-II
determined by a standard zone of inhibition assay
against Gram-positive and Gram-negative bacteria. (A–
C) The purified protein CaTx-II displayed the most potent growth
inhibitory (millimeter in diameter) potential against B. pseudomallei,
S. aureus and E. aerogenes than the separated fraction (CA-F1) and
crude venom. (CA-CV). Clear zone of inhibition measured around
the disc after 24 h incubation at 37uC. (D–E) The antimicrobial
potency of CaTx-II was almost equal when compared to that of
commercial antibiotics such as CHL-chloramphenicol and Stp-
stretomycin against tested bacteria.
(TIF)
Figure S3 Bacteriostatic effect of CaTx-II was deter-
mined by MH and TS broth dilution method at different
doses (3.9–250 mg/ml) incubated with bacteria (105–
106 CFU/ml) for 24 h at 376C. Bacterial turbidity was
measured spectrophotometrically at 560 nm. Each optical density
(OD) values represents the mean 6 SD of three replicates (n = 3).
The MIC values represented by (#) of each Gram-positive and
Gram-negative bacteria (A) B. pseudomallei KHW (MIC of 7.8 mg/
ml), (B) B. pseudomallei TES (MIC of 15.6 mg/ml), (C) S. aureus
(MIC of 7.8 mg/ml), (D) E. aerogenes (MIC of 31.25 mg/ml), (E) P.
vulgaris (MIC of 31.25 mg/ml), (F) P. mirabilis (MIC of 62.5 mg/ml),
(G) K. pneumoniae (MIC of 62.5 mg/ml), (H) S. pneumoniae (MIC of
250 mg/ml), (I) P. aerogenes (MIC of 125 mg/ml).
(TIF)
Figure S4 In vitro bactericidal activity of CaTx-II on
bacteria. Different concentrations of protein (3.9–250 mg/ml)
were serially diluted with MH and TS broth containing (105–
106 CFU/ml). 50 ml of this sample was added to 96-well plates
and incubated at 37uC for 24 h. After incubation, 20 ml of the
sample was applied onto MH and TS agar plates and viable
counts of the bacteria recorded after 24 h. The CFU of each point
represents mean 6 SD of triplicate counts (n = 3).
(TIF)
Table S1. The N-terminal amino acid sequences of
purified PLA2 protein (CaTx-II) from Crotalus adamanteus
was compared with other snake venom PLA2s such as
PA2A_CRODU-Crotoxin acid chain (Crotalus durissus terrificus),
PA2A_CROSS-Mojave toxin acidic chain (Crotalus scutulatus
scutulatus), PA21B_TRIGA-PLA2 isozyme (Trimeresurus grami-
neus), PA2_CROAT-PLA2 (Crotalus atrox), PA2C_AGKRH-
PLA2 (Agkistrodon rhodostoma), PA2_BOTPC-PLA2 (Bothrops
pictus), PA21_ECHCO-PLA2 (Echis coloratus), PA2B2_BOTJR-
bothropstoxin-2 (Bothrops jararacussu), PA25_ECHPL-PLA2
(Echis pyramidum leakeyi), PA21_BOTAS-PLA2 (Bothrops asper).
(DOC)
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